J&J strikes landmark deal with Trump administration to lower drug prices, avoid tariffs
Johnson & Johnson (NYSE:JNJ) became the latest pharmaceutical titan to bow to White House pressure, announcing a voluntary agreement to lower prescription drug costs in exchange for an exemption from the administration’s aggressive new import tariffs.






-640x358.jpg&w=3840&q=75)


-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)


-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)

-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)


-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)